Discussion
epithelial damage, deaths, asthma
ASTHMA
This study was terminated early due to the high rate of screen failure, low enrollment, and unlikely feasibility of timely study completion. While other factors such as viruses, pollens, and chitin can induce or trigger IL-33 release, the choice to restrict the study to a single population (asthma) with a specific common inciting factor (fungal sensitization) associated with epithelial damage was made to eliminate any potential differences in the biological effect based on the inciting trigger [GSK3772847 exposures were generally consistent with observations in previous clinical studies. Target engagement was confirmed via a significant reduction in free sST2 levels and an increase in total sST2, consistent with results from the previously reported Phase I study [No deaths occurred in this study and the safety observations are consistent with the known safety profile of GSK3772847.Besides impacting sST2 levels, no conclusions can be drawn due to the early termination of the study and low population size. Nevertheless, it may be valuable to further evaluate the efficacy and safety of GSK3772847 in a larger population with moderate-to-severe asthma with AFAD.